M
Masakazu Toi
Researcher at Kyoto University
Publications - 658
Citations - 28522
Masakazu Toi is an academic researcher from Kyoto University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 69, co-authored 578 publications receiving 23200 citations. Previous affiliations of Masakazu Toi include The Breast Cancer Research Foundation & Tokyo Metropolitan Komagome Hospital.
Papers
More filters
Journal ArticleDOI
Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer (BMC Cancer (2019) 19 (517) DOI: 10.1186/s12885-019-5687-0)
Edith A. Perez,Sanne de Haas,Wolfgang Eiermann,Carlos H. Barrios,Masakazu Toi,Young-Hyuck Im,Pierfranco Conte,Miguel Martin,Tadeusz Pienkowski,Xavier Pivot,Howard A. Burris,Sven Stanzel,Monika Patre,Paul Ellis +13 more
TL;DR: Following publication of the original article [1], the authors reported the following errors in the article.
Journal ArticleDOI
Occurrence of senescence-escaping cells in doxorubicin-induced senescence is enhanced by PD0332991, a cyclin-dependent kinase 4/6 inhibitor, in colon cancer HCT116 cells.
TL;DR: The present study investigated the relevance of the cell cycle phase and colony formation in the DOX-induced senescence of human colon cancer HCT116 cells and co-treatment of PD0332991 with DOX slowed progression of cells in the G1 phase resulting in enhanced colony formation.
Journal ArticleDOI
Effect of dose timing on the blood concentration of lapatinib in patients with breast cancer.
Masahiro Ohgami,Hiroko Bando,Hiroshi Ishiguro,Moe Tsuda,N. Toriguchi,K. Aogi,Masakazu Toi,Noriyuki Masuda,S. Mitsuhashi,A. Kurosawa,Masato Homma +10 more
Journal ArticleDOI
Neoadjuvant exemestane for 24 weeks in postmenopausal women with hormone receptor positive stage II or IIIA breast cancer (JFMC34–0601)
Nobuaki Sato,Noriyuki Masuda,Shigetoyo Saji,Hiroyuki Takei,Yutaka Yamamoto,Hironobu Sasano,Masakazu Toi +6 more
TL;DR: Exemestane has shown attractive response for hormone receptor positive breast cancer in neoadjuvant setting with sufficient safety and tolerability, and central pathological review exhibited that biomarker changes during the treatment correlated with tumor response.
Journal Article
[5'-deoxy-5-fluorouridine (5'-DFUR), mitomycin C (MMC), etoposide and medroxy progesterone acetate (MPA) in a previously treated patient with advanced breast cancer].
TL;DR: An advanced breast cancer patient refractory to CAF, 5-FU-Methotrexate sequential therapy and Tamoxifen was treated with the combination 5' DFUR, MMC, Etoposide and MPA, and it is suggested that the combination therapy may be useful for previously treated patients withAdvanced breast cancer.